Evidence grows that these nonclinical factors have a large influence on patient outcomes. Here’s what hospitals and payers can do about it.
Machine learning is helping scientists better understand the development of mental health conditions—and the best ways to help treat them.
COPD is a chronic, progressive disorder that can lead to early death. Here are some ways to help mitigate the risk of developing this debilitating disorder.
Your favorite app store is likely filled with many mental health offerings. But what can they really offer?
With all eyes on drug prices, payers are looking to biosimilar agents to cut costs—and improve patient outcomes.
The biosimilar market is flourishing in Europe—why aren’t we seeing similar gains in the U.S.?
Biosimilar agents can help healthcare organizations offer patients more options for their care. So, what’s stopping payers from immediately adding them to their formularies?
As healthcare organizations move toward value-based models of reimbursement, high drug prices can sometimes get in the way of optimal care. Here are three ways that biosimilars may help.
This evidence-based training program can help communities better understand how to connect, not correct, individuals who may be struggling with mental health issues.
It can be challenging for patients with schizophrenia to keep to a medication regimen—here are the reasons why it’s important to invest in strategies to help them stay compliant.